IL-1-induced ERK1/2 activation up-regulates p21Waf1/Cip1 protein by inhibition of degradation via ubiquitin-independent pathway in human melanoma cells A375

Biochemical and Biophysical Research Communications

Volumn 392, Issue 3, 2010, Pages 369-372

  Arakawa, Tomohiro ^a   Hayashi, Hidetoshi ^a   Itoh, Saotomo ^a   Takii, Takemasa ^a   Onozaki, Kikuo ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

ERK1 2; IL 1; Melanoma; p21Waf1 Cip1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIN DEPENDENT KINASE INHIBITOR 1; INTERLEUKIN 1; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P21; UBIQUITIN;

ARTICLE; DRUG INHIBITION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; UBIQUITINATION; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; INTERLEUKIN-1; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; UBIQUITIN; UP-REGULATION;

EID: 76349105022     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.027     Document Type: Article

References (26)

1. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H., Zhang P., Dobrowolski S., Bai C., Connell-Crowley L., Swindell E., Fox M.P., and Wei N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6 (1995) 387-400
2. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
3. Coleman M.L., Marshall C.J., and Olson M.F. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J. 22 (2003) 2036-2046
4. Rousseau D., Cannella D., Boulaire J., Fitzgerald P., Fotedar A., and Fotedar R. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene 18 (1999) 4313-4325
5. Sheaff R.J., Singer J.D., Swanger J., Smitherman M., Roberts J.M., and Clurman B.E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell 5 (2000) 403-410
6. Blagosklonny M.V., Wu G.S., Omura S., and el-Deiry W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 227 (1996) 564-569
7. Wang W., Nacusi L., Sheaff R.J., and Liu X. Ubiquitination of p21Cip1/WAF1 by SCFSkp2: substrate requirement and ubiquitination site selection. Biochemistry 44 (2005) 14553-14564
8. Li Y., Dowbenko D., and Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 277 (2002) 11352-11361
9. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
10. Bendtzen K., Mandrup-Poulsen T., Nerup J., Nielsen J.H., Dinarello C.A., and Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232 (1986) 1545-1547
11. Maier J.A., Voulalas P., Roeder D., and Maciag T. Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science 249 (1990) 1570-1574
12. Gaffney E.V., and Tsai S.C. Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin 1. Cancer Res. 46 (1986) 3834-3837
13. Onozaki K., Urawa H., Tamatani T., Iwamura Y., Hashimoto T., Baba T., Suzuki H., Yamada M., Yamamoto S., Oppenheim J.J., and Matsushima K. Synergistic interactions of interleukin,1 interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor. J. Immunol. 140 (1988) 112-119
14. Kilian P.L., Kaffka K.L., Biondi D.A., Lipman J.M., Benjamin W.R., Feldman D., and Campen C.A. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH:OVCAR-3). Cancer Res. 51 (1991) 1823-1828
15. Fryling C., Dombalagian M., Burgess W., Hollander N., Schreiber A.B., and Haimovich J. Purification and characterization of tumor inhibitory factor-2: its identity to interleukin 1. Cancer Res. 49 (1989) 3333-3337
16. Onozaki K., Matsushima K., Aggarwal B.B., and Oppenheim J.J. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J. Immunol. 135 (1985) 3962-3968
17. Morinaga Y., Suzuki H., Takatsuki F., Akiyama Y., Taniyama T., Matsushima K., and Onozaki K. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines. J. Immunol. 143 (1989) 3538-3542
18. Endo Y., Matsushima K., Onozaki K., and Oppenheim J.J. Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor. J. Immunol. 141 (1988) 2342-2348
19. Yang D., Hayashi H., Takii T., Mizutani Y., Inukai Y., and Onozaki K. Interleukin-1-induced growth inhibition of human melanoma cells. Interleukin-1-induced antizyme expression is responsible for ornithine decarboxylase activity down-regulation. J. Biol. Chem. 272 (1997) 3376-3383
20. Morinaga Y., Hayashi H., Takeuchi A., and Onozaki K. Antiproliferative effect of interleukin 1 (IL-1) on tumor cells: G0-G1 arrest of a human melanoma cell line by IL-1. Biochem. Biophys. Res. Commun. 173 (1990) 186-192
21. Itoh S., Hattori T., Hayashi H., Mizutani Y., Todo M., Takii T., Yang D., Lee J.C., Matsufuji S., Murakami Y., Chiba T., and Onozaki K. Antiproliferative effect of IL-1 is mediated by p38 mitogen-activated protein kinase in human melanoma cell A375. J. Immunol. 162 (1999) 7434-7440
22. Arakawa T., Yamamura T., Hattori T., Hayashi H., Mori A., Yoshida A., Uchida C., Kitagawa M., and Onozaki K. Contribution of extracellular signal-regulated kinases to the IL-1-induced growth inhibition of human melanoma cells A375. Int. Immunopharmacol. 8 (2008) 80-89
23. Meloche S., and Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 (2007) 3227-3239
24. Todd D.E., Densham R.M., Molton S.A., Balmanno K., Newson C., Weston C.R., Garner A.P., Scott L., and Cook S.J. ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene 23 (2004) 3284-3295
25. Shirako E., Hirayama N., Tsukada Y., Tanaka T., and Kitamura N. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation. J. Cell. Biochem. 104 (2008) 176-188
26. Treier M., Staszewski L.M., and Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78 (1994) 787-798